The iCRT (inhibitor of β-catenin responsive transcription) SMIs also inhibit β-catenin and TCF/LEF interaction, and iCRT3 has shown some promise in normal karyotype AML and acute lymphoblastic leukaemia (ALL) [108]. Here, HNF4A is linked to acute lymphoblastic leukemia.